H. Lundbeck A/S
HLUN B
ISIN DK0061804770 / Valor 119252587
H. Lundbeck A/S
UMushroom community rating:
About company
H. Lundbeck A/S is a global pharmaceutical company headquartered in Denmark, with a presence in over 50 countries. The company specializes in developing and marketing innovative treatments for brain diseases, leveraging its production facilities in Denmark, France, and Italy, and research centers in Denmark and the United States. Since its public listing on Nasdaq Copenhagen in 1999, Lundbeck has been primarily owned by the Lundbeck Foundation, which holds approximately 70% of its shares and supports medical research and educational initiatives. With a history spanning over 70 years, Lundbeck has been instrumental in providing therapies that address neurological and psychiatric disorders, impacting millions of patients worldwide.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (01.10.2025):
H. Lundbeck A/S reported robust financial performance for the year 2024, demonstrating significant growth in revenue and profitability compared to the previous year.
Revenue Growth
Revenue increased to DKK 22,004 million in 2024, up from DKK 19,912 million in 2023, reflecting a strong market position and effective sales strategies.
Operating Profit
The operating profit before depreciation and amortization (EBITDA) stood at DKK 5,146 million in 2024, slightly decreasing from DKK 5,207 million in 2023. However, the profit from operations (EBIT) rose to DKK 3,270 million compared to DKK 3,195 million the previous year.
Net Profit
Net profit for the year reached DKK 3,143 million in 2024, a notable increase from DKK 2,290 million in 2023, driven by improved operational efficiency and cost management.
Cash Flow
Cash flows from operating activities were DKK 3,326 million in 2024, while investing activities saw significant investments totaling DKK -15,286 million. Financing activities contributed positively with DKK 11,629 million.
Balance Sheet Strength
Total assets grew to DKK 56,976 million in 2024 from DKK 37,407 million in 2023, supported by an increase in non-current assets and equity, which rose to DKK 25,010 million.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
5402 M
Market cap (USD)
575,958
Daily traded volume (Shares)
42.24 / 41.3
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
